Harvard Bioscience (HBIO) Competitors

Harvard Bioscience (NASDAQ:HBIO) and Thermo Fisher Scientific (NYSE:TMO) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.

Is HBIO or TMO more profitable?

Thermo Fisher Scientific has a net margin of 14.48% compared to Harvard Bioscience's net margin of -14.57%. Thermo Fisher Scientific's return on equity of 17.49% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-14.57%	-4.64%	-2.40%
Thermo Fisher Scientific	14.48%	17.49%	8.36%

Does the MarketBeat Community prefer HBIO or TMO?

Thermo Fisher Scientific received 708 more outperform votes than Harvard Bioscience when rated by MarketBeat users. Likewise, 81.09% of users gave Thermo Fisher Scientific an outperform vote while only 72.02% of users gave Harvard Bioscience an outperform vote.

Company	Underperform	Outperform
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%
Thermo Fisher Scientific	Outperform Votes 1076 81.09%	Underperform Votes 251 18.91%

Do institutionals & insiders have more ownership in HBIO or TMO?

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 9.0% of Harvard Bioscience shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more volatility & risk, HBIO or TMO?

Harvard Bioscience has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Do analysts prefer HBIO or TMO?

Thermo Fisher Scientific has a consensus target price of $652.30, indicating a potential upside of 24.47%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Thermo Fisher Scientific	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.86

Which has stronger valuation and earnings, HBIO or TMO?

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$97.73M	0.94	-$3.41M	-$0.33	-6.39
Thermo Fisher Scientific	$42.37B	4.73	$6.00B	$15.95	32.86

Does the media favor HBIO or TMO?

In the previous week, Thermo Fisher Scientific had 10 more articles in the media than Harvard Bioscience. MarketBeat recorded 11 mentions for Thermo Fisher Scientific and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.98 beat Thermo Fisher Scientific's score of 0.59 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 16 of the 19 factors compared between the two stocks.